Acarbose in Non-insulin-dependent Diabetes Mellitus: Short-term Studies in Combination with Oral Agents

  • B. Willms

Abstract

Type II diabetes mellitus (non-insulin-dependent diabetes mellitus, NIDDM) is a disease with increasing prevalence in western civilized countries. One reason for this is that the incidence of type II diabetes increases with age and, as people are growing older and older, type II diabetes concomitantly increases with the longevity of the population.

Keywords

Fermentation Starch Carbohydrate Fructose Lactose 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goetz F (1985) Paper given at the XII IDF-Congress in Madrid, September 28, 1985Google Scholar
  2. 2.
    Herman WH, Teutsch SM, Sepe SJ, Sinnock P, Klein R (1983) An approach to the prevention of blindness in diabetes. Diabetes Care 6:608–613PubMedCrossRefGoogle Scholar
  3. 3.
    Hillebrand I, Boehme K (1982) Clinical studies on acarbose during 5 years. In: Creutzfeldt W (ed) First international Symposium on acarbose. Excerpta Medica, Amsterdam, pp 445–450Google Scholar
  4. 4.
    Hillebrand I, Englert R, Boehme K, Schulz H (1987) Kontrollierte 3monatige Studie bei Typ-II-Diabetikern. Vergleich zweier Glucosidaseinhibitoren (Acarbose und Miglitol) mit Glibenclamid. Akt Endokrin Stoffw 8:83Google Scholar
  5. 5.
    Jenkins DJA, Taylor RH (1982) Acarbose: dosage and interaction with sugars, starch and fibre. In: Creutzfeldt W (ed) First international symposion on acarbose. Excerpta Medica, Amsterdam, pp 86–96Google Scholar
  6. 6.
    Johansen K (1984) Acarbose treatment of sulfonylurea-treated noninsulin dependent diabetics. A doubleblind crossover comparison of an α-glucosidase inhibitor with metformin. Diebète Metabol 10:219–223Google Scholar
  7. 7.
    Krolewski AS, Warram JH (1985) Epidemiology of diabetes mellitus. In: Marble A et al. (eds) Joslin’s diabetes mellitus. Lea and Febiger, Philadelphia, pp 12–42Google Scholar
  8. 8.
    Krolewski AS, Warram JH, Christlieb AR (1985) Onset, course, complications, and prognosis of diabetes mellitus. In: Marble A et al. (eds) Joslin’s diabetes mellitus. Lea and Febiger, Philadelphia, pp 251–277Google Scholar
  9. 9.
    Mies R, Spengler M (1987) Efficacy of the glucosidase inhibitor acarbose compared to the sulphonylurea glisoxepid on metabolic control of type-2-diabetes. Diabetologia 30:557AGoogle Scholar
  10. 10.
    Sachse G, Willms B (1979) Effect of the a-glucosidase inhibitor BAY g 5421 on blood glucose control of sulphonylurea treated diabetics and insulin treated diabetics. Diabetologia 17:287–290PubMedCrossRefGoogle Scholar
  11. 11.
    Schwedes U, Petzoldt R, Hillebrand I, Schöffling K (1982) Comparison of acarbose and metformin treatment in non-insulin-dependent diabetic outpatients. In: Creutzfeldt W (ed) First international symposion on acarbose. Excerpta Medica, Amsterdam, pp 275–281Google Scholar
  12. 12.
    Willms B, Sachse G, Unger H (1980) Treatment of diabetes with a glycoside-hydrolase inhibitor (acarbose, BAY g 5421). In: Creutzfeldt W (ed) Frontier in hormone research. Karger, Basel, pp 276–281Google Scholar
  13. 13.
    Worlicek H, Schneider M, Kolb S, Sailer D (1982) Treatment of non-insulin dependent diabetic adults with acarbose: the effect of dosage division. In: Creutzfeldt W (ed) First international symposion on acarbose. Excerpta Medica, Amsterdam, pp 313–316Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • B. Willms
    • 1
  1. 1.Fachklinik für Diabetes und StoffwechselkrankheitenBad Lauterberg im HarzGermany

Personalised recommendations